Q-omics provides the consensus-scored IRX1 profile across patient tissues and cancer cell-line models. IRX1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, IRX1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, IRX1 RNA expression shows 13,817 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where IRX1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IRX1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IRX1 survival associations across molecular data types. IRX1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IRX1 RNA expression–survival associations across cancer types. High IRX1 expression shows unfavorable associations in UVM, KIRP, READ and LUSC, but favorable associations in MESO and LAML. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for IRX1 RNA expression.
This table summarizes IRX1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for IRX1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IRX1 shows lower tumor expression in KICH, KIRP, KIRC, LUAD, LUSC and BRCA. The KICH box plot shows higher IRX1 RNA expression in normal versus tumor tissue (log2 FC = −5.815, t-test p < 0.001).
This table shows molecular features associated with IRX1 in patient tissues and cancer cell lines. In patient samples, IRX1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IRX1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
